Affordable Access

deepdyve-link deepdyve-link
Publisher Website

MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.

Authors
  • Jin, Hyun Yong
  • Oda, Hiroyo
  • Lai, Maoyi
  • Skalsky, Rebecca L
  • Bethel, Kelly
  • Shepherd, Jovan
  • Kang, Seung Goo
  • Liu, Wen-Hsien
  • Sabouri-Ghomi, Mohsen
  • Cullen, Bryan R
  • Rajewsky, Klaus
  • Xiao, Changchun
Type
Published Article
Journal
The EMBO Journal
Publisher
EMBO
Publication Date
Aug 28, 2013
Volume
32
Issue
17
Pages
2377–2391
Identifiers
DOI: 10.1038/emboj.2013.178
PMID: 23921550
Source
Medline
License
Unknown

Abstract

MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17~92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation. Here we show that B cell-specific miR-17~92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17~92. We experimentally identified miR-17~92 target genes by PAR-CLIP and validated select target genes in miR-17~92 transgenic mice. These analyses demonstrate that miR-17~92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NFκB pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17~92-driven lymphoma cells exhibited constitutive activation of the PI3K and NFκB pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice. These findings establish miR-17~92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation.

Report this publication

Statistics

Seen <100 times